Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Egypt. J. Exp. Biol. (Zoo.). 2007; 3(0): 127-133


AMELIORATIVE ROLE OF SILYMARIN AGAINST RIBAVIRIN INDUCED TOXICITY IN THE KIDNEY OF ALBINO RAT

Sabah F El-Abd, Yosry Okda.




Abstract

Ribavirin is the first anti-C and other virus drug all over the world. Silymarin is one of the hepatoprotective drugs that belong to the group of free-radical scavengers. The present work was planned to investigate the histo-pathological, histochemical and biochemical effects of ribavirin on the kidney of albino rats. Treating animals with prescribed dose of ribavirin (12mg/kg body weight in bi-distilled water twice a day) for one, two and three weeks induced many histopathological, histochemical and biochemical changes in the kidney. After two weeks of treatment with ribavirin, the blood vessels were congested with atrophy of kidney glomeruli, degeneration of renal tubules and depletion of glycogen and total protein contents in the kidney tissues. Intraperitoneal injection of silymarin simultaneous with ribavirin at a dose level (250 mg/ kg body weight in bi-distilled water twice a day) for one, two and three weeks reduced the histopathological, histochemical, and biochemical lesions that induced by ribavirin. In conclusion, the present study showed that ribavirin affects the structure and function of the kidney, whereas silymarin had a protective effect.

Key words: Ribavirin- Silymarin- Kidney- Pathology- Histochemistry- Biochemistry.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.